Q-omics provides the consensus-scored ABHD16A profile across patient tissues and cancer cell-line models. ABHD16A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ABHD16A is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, ABHD16A RNA expression shows 20,920 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KICH, and ACC as cancer lineages where ABHD16A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD16A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD16A survival associations across molecular data types. ABHD16A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD16A RNA expression–survival associations across cancer types. High ABHD16A expression shows unfavorable associations in UVM and COAD, but favorable associations in READ, BLCA, PAAD and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for ABHD16A RNA expression.
This table summarizes ABHD16A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ABHD16A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD16A shows lower tumor expression in KICH and higher tumor expression in LIHC, COAD, STAD, BRCA and CHOL. The KICH box plot shows higher ABHD16A RNA expression in normal versus tumor tissue (log2 FC = −1.228, t-test p < 0.001).
This table shows molecular features associated with ABHD16A in patient tissues and cancer cell lines. In patient samples, ABHD16A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD16A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
